RESUMO
Sarcoidosis is a granulomatous disease of unknown etiology that can affect almost any organ. Although the acute form can have spontaneous regression, a certain number of patients can have a chronic form, which leads to an increase in mortality and a decrease in the quality of life. Considering that the risk factors are still unknown, we wanted to compare the characteristics of patients with acute and chronic forms of sarcoidosis in Serbia in order to determine significant differences between them with hopes of contributing to everyday clinical practice. A total of 2380 patients treated in our clinic were enrolled in this study. They were separated into the following two groups: 1126 patients with acute form and 1254 patients with chronic form. They were further compared by gender, smoking status, radiological status, exposition, biomarkers for sarcoidosis, organ involvement, and other comorbidities; the distribution of patients according to regions of Serbia was also noted. Statistical significance was found in radiological findings (p < 0.001), biomarkers (calcium in 24 h urine p < 0.001; chitotriosidase p = 0.001), and the affliction of organs (p < 0.001). The differences noted in this paper could help improve our understanding of this disease.
RESUMO
Gaucher disease (GD) is a lysosomal storage disorder with glucocerebroside accumulation in the macrophages. The disease is divided into three types based on neurocognitive involvement with GD1 having no involvement while the acute (GD2) and chronic (GD3) are neuronopathic. The non-neurological symptoms of GD3 are well treated with enzyme replacement therapy (ERT) which has replaced hematopoietic stem cell transplantation (HSCT). ERT is unable to prevent neurological progression as the enzyme cannot cross the blood-brain barrier. In this retrospective study, we report the general, neurocognitive, and biochemical outcomes of three siblings with GD3 after treatment with ERT or HSCT. Two were treated with HSCT (named HSCT1 and HSCT2) and one with ERT (ERT1). All patients were homozygous for the c.1448 T > C, (p.Leu483Pro) variant in the GBA1 gene associated with GD3. ERT1 experienced neurocognitive progression with development of seizures, oculomotor apraxia, perceptive hearing loss and mental retardation. HSCT1 had no neurological manifestations, while HSCT2 developed perceptive hearing loss and low IQ. Chitotriosidase concentrations were normal in plasma and cerebrospinal fluid (CSF) for HSCT1 and HSCT2, but both were markedly elevated in ERT1. We report a better neurological outcome and a normalization of chitotriosidase in the two siblings treated with HSCT compared to the ERT-treated sibling. With the advancements in HSCT over the past 25 years, we may reconsider using HSCT in GD3 to achieve a better neurological outcome and limit disease progression.
Assuntos
Terapia de Reposição de Enzimas , Doença de Gaucher , Glucosilceramidase , Transplante de Células-Tronco Hematopoéticas , Humanos , Doença de Gaucher/terapia , Doença de Gaucher/genética , Doença de Gaucher/tratamento farmacológico , Masculino , Feminino , Glucosilceramidase/genética , Glucosilceramidase/uso terapêutico , Estudos Retrospectivos , Criança , Resultado do Tratamento , Irmãos , Adolescente , Hexosaminidases/genética , Pré-EscolarRESUMO
BACKGROUND: Cystine-depleting therapy in nephropathic cystinosis is currently monitored via the white blood cell cystine assay, although its application and usefulness are limited by practical and technical issues. Therefore, alternative biomarkers that are widely available, more economical and less technically demanding, while reliably reflecting long-term adherence to cysteamine treatment, are desirable. Recently, we proposed chitotriosidase enzyme activity as a potential novel biomarker for the therapeutic monitoring of cysteamine treatment in cystinosis. In this study, we aimed to validate our previous findings and to confirm the value of chitotriosidase in the management of cystinosis therapy. MATERIALS & METHODS: A retrospective study was conducted on 12 patients treated at the National Institutes of Health Clinical Center and followed up for at least 2 years. Plasma chitotriosidase enzyme activity was correlated with corresponding clinical and biochemical data. RESULTS: Plasma chitotriosidase enzyme activity significantly correlated with WBC cystine levels, cysteamine total daily dosage and a Composite compliance score. Moreover, plasma chitotriosidase was a significant independent predictor for WBC cystine levels, and cut-off values were established in both non-kidney transplanted and kidney transplanted cystinosis patients to distinguish patients with a good versus poor compliance with cysteamine treatment. Our observations are consistent with those of our previous study and validate our findings. CONCLUSIONS: Chitotriosidase enzyme activity is a valid potential alternative biomarker for monitoring cysteamine treatment in nephropathic cystinosis patients. SYNOPSIS: Chitotriosidase enzyme activity is a valid potential alternative biomarker for monitoring cysteamine treatment in nephropathic cystinosis patients.
Assuntos
Cisteamina , Cistina , Cistinose , Hexosaminidases , Humanos , Cisteamina/uso terapêutico , Masculino , Feminino , Cistinose/tratamento farmacológico , Cistinose/sangue , Estudos Retrospectivos , Hexosaminidases/sangue , Adolescente , Cistina/sangue , Criança , Adulto , Biomarcadores/sangue , Adulto Jovem , Monitoramento de Medicamentos/métodos , Eliminadores de Cistina/uso terapêutico , Pré-Escolar , Transplante de RimRESUMO
La enfermedad de Gaucher es un trastorno de herencia autosómica recesiva y la enfermedad de depósito lisosomal más frecuente causada por deficiencia de la actividad enzimática de la β-Glucosidasa. Objetivo: establecer valores de referencia de actividad enzimática lisosomal de β-glucosidasa y quitotriosidasa en lactantes en población Venezolana. Método: Se realizó un estudio prospectivo y transversal en 98 lactantes sanos con edades comprendidas entre 1 mes y 24 meses, de ambos sexos (48 femeninos y 50 masculinos). La actividad enzimática de β-glucosidasa y quitotriosidasa fue determinada en gotas de sangre seca (siglas en inglés, DBS) siguiendo el protocolo propuesto por Chamoles y col. El análisis estadístico de los datos se realizó con el programa estadístico SPSS Statistics 17.0 para Windows. Resultados: El rango de actividad enzimática para la β-Glucosidasa obtenido en esta investigación fue 2,3 - 12 nmol/ml/h, con una media de 6,7 ± 2,5 y para la Quitotriosidasa 0 - 44,2 nmol/ml/h con una media de 18,4 ± 10,4 nmol/ml/h, utilizando discos de papel de filtro de 3mm de diámetro con sangre seca (aproximadamente 3,6 μl de sangre). Conclusión: Los valores de referencia de actividad enzimática lisosomal en DBS para β-glucosidasa y quitotriosidasa son establecidos por vez primera en lactantes sanos venezolanos; no obstante, estos resultados difieren con los reportados en estudios internacionales, recomendándose la determinación de valores de referencias autóctonos en diferentes grupos etarios.
Gaucher´s Disease is an autosomal recessive disorder and the most common lysosomal storage disease caused by deficiency of β-glucosidase enzyme activity. Objetive: to establish reference values for lysosomal enzyme activity of β-glucosidase and chitotriosidase in Venezuelan infants. Methods:A prospective cross-sectional study was conducted in 98 healthy infants with ages ranging from 1 month to 24 months (48 females and 50 males). Enzymatic activity of β-glucosidase and chitotriosidase were determined in dried blood spots (DBS) following the protocol by Chamoles et al. Statistical analysis of data was performed with software SPSS 17.0 for Windows Statistics. Results: The range of enzymatic activity for β-glucosidase was 2.3 to 12 nmol/ml/h, with an average of 6.7 ± 2.5. Chitotriosidase activity was from 0 to 44.2 nmol/ml/h with an average of 18.4 ± 10.4 using 3mm diameter discs of filter paper with dried blood (approximately 3.6 μl of blood). Conclusions: The reference values of lysosomal enzyme activity in DBS for β-Glucosidase and quitotriosidase were established for the first time in healthy Venezuelan infants; however, these results differ from those reported in international studies, for which reason autochthonous reference values should be determined in different age groups.